Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
May 06 2019 - 8:39PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated
pharmaceutical company pioneering time-dependent medicines for
central nervous system (CNS) disorders, today announced that
posters regarding GOCOVRITM (amantadine) extended release capsules
for the treatment of dyskinesia in patients with Parkinson's
disease receiving levodopa-based therapy, with or without
concomitant dopaminergic medications, and ADS-5102 (amantadine)
extended release capsules for walking impairment in patients with
multiple sclerosis (MS) will be presented at the 71st Annual
American Academy of Neurology (AAN) Meeting being held May 4-10,
2019 in Philadelphia.
"New data from our two-year open label study suggest chronic
GOCOVRI treatment may enable the dose of dopaminergic medications
to be modified with an improvement in OFF and dyskinesia. We hope
these data, coupled with the GOCOVRI pivotal program, can provide
confidence to neurologists to increase the use of dopaminergic
therapies alongside adjunctive GOCOVRI to benefit their PD
patients," said Rajiv Patni, MD, Chief Medical Officer of Adamas.
"In addition, we're looking forward to discussing the baseline
demographics and study design features of INROADS, our ongoing
Phase 3 study to assess the potential efficacy and safety of
ADS-5102 for walking impairment in patients with MS."
Details of the poster presentations are
below:
GOCOVRI Poster PresentationTitle: Changes to
Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with
Dyskinesia While on GOCOVRITM (amantadine) Extended Release
Capsules: A Two-Year Phase 3 Open Label Study AnalysisPresenter:
Dr. Stuart Isaacson, Parkinson's Disease & Movement Disorders
Center of Boca RatonPoster ID: P4.7-010Poster Session 4:
Movement Disorders ePoster SessionDate and Time: Thursday, May 9,
2019; 11:30 a.m. – 6:30 p.m. ET ADS-5102 Poster
PresentationTitle: INROADS: A Phase 3 Study to Assess the
Efficacy and Safety of ADS-5102 (amantadine) Extended Release
Capsules in Multiple Sclerosis Patients with Walking
ImpairmentPresenter: Dr. Michelle Cameron, Oregon Health and
Science University Poster ID: P5.2-087Poster Session 5: MS Symptom
Assessment and ManagementDate and Time: Wednesday, May 9, 2019;
11:30 a.m. – 6:30 p.m. ET
About GOCOVRI QHS GOCOVRITM (amantadine)
extended-release capsules is the first and only FDA-approved
medicine indicated for the treatment of dyskinesia in patients with
Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications. It is also the only
medicine proven to reduce both dyskinesia and OFF.
GOCOVRI is thought to work by reducing the amount of glutamate
hyperactivity in a region of the brain that controls movement, in
patients experiencing dyskinesia and OFF. The NMDA receptor is
activated by glutamate and causes post-synaptic nerve signaling in
this area of the brain, which is modulated by dopamine.
Levodopa therapy replaces dopamine lost in Parkinson’s disease but
may result in large fluctuations in synaptic levels of dopamine
during waking hours, further exacerbating glutamate hyperactivity.
GOCOVRI, developed by Adamas, is novel in that it selectively
blocks the NMDA receptor in a time-dependent manner. Taken at
bedtime (QHS), GOCOVRI provides an initial lag and a slow rise in
amantadine concentration during the night and a high concentration
from the morning and throughout the waking day. Additionally,
the adjunctive use of GOCOVRI does not require dose changes to
dopaminergic therapies. The most common side effects of
GOCOVRI include dry mouth, swelling of legs and feet, constipation,
and falls.
For more information about GOCOVRI, please see the U.S.
Prescribing Information at www.GOCOVRI.com.
About ADS-5102 Adamas is currently evaluating
ADS-5102 in a Phase 3 clinical program for walking impairment in
patients with multiple sclerosis. ADS-5102 was previously approved
by the FDA under the trade name GOCOVRI™ (amantadine) extended
release capsules for the treatment of dyskinesia in patients with
Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications. GOCOVRI is not
FDA-approved for the treatment of walking impairment in patients
with multiple sclerosis.
About Adamas Pharmaceuticals, Inc. Adamas’
goal is to create and commercialize a new generation of medicines
intended to lessen the burden of chronic neurologic diseases on
patients, caregivers and society using its deep understanding of
time-dependent biology. The Company is focused on the
commercialization of GOCOVRI™ (amantadine) extended release
capsules, the first and only FDA-approved medicine for the
treatment of dyskinesia in patients with Parkinson’s disease
receiving levodopa-based therapy, with or without concomitant
dopaminergic medications. The Company also continues to deliver
differentiated investigational programs, including ADS-5102 in
development for the treatment of walking impairment in patients
with multiple sclerosis. For more information about Adamas and its
unique approach to developing medicines based on time-dependent
biology, please visit www.adamaspharma.com.
Contacts: Investors: Peter Vozzo Westwicke
Partners 443-213-0505Peter.vozzo@westwicke.com
Media: Sarah Mathieson Vice President, Communications and
Engagement 510-450-3528 smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2024 to May 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2023 to May 2024